Postoperative Massive Bleeding in a Patient with Hemophilia A Undergoing Brain Surgery: A Case Report
Keywords:
Hemophilia, InhibitorAbstract
Abstract: A Thai boy with atypical Kawasaki disease receiving aspirin with undiagnosed hemophilia, was reported. He exhibited bleeding in the brain requiring craniotomy. At postoperation, massive bleeding occurred due to high inhibitor of 170 Bethesda units to the factor VIII clotting activity. Several bypassing agents were administered to save his life.
Downloads
References
Montgomery RR, Scott JP. Hemophilia A and B. In: Nathan DG, Oski: FA, eds. Hematology of infancy and childhood. 5 ed. Philadelphia: WB. Saunders 1998:1613-59.
Isarangkura P, Bintadit P, Hathirat P, et al. Study of prevalence of hereditary bleeding disorders in Thailand. Vajira Med J 1980;24:183-90.
Gringeri A, Mantovani LG, Scalone L, Mannucci PM; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102:2358-63.
Thompson AR. Structure and functional of the factor VIIl gene and protein. Semin Thromb Hemost 2003;29:11-22.
Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients-a review of recent studies of recombinant and plasma-derived factor VII concentrates. Haemophilia 1999;5:145-54.
Aledort L. Inhibitors in hemophilia patients: current status and management. Am J Hematol 1994;47:208-17
Fijnvandraat K, Bril WS, Vooberg J. Immunobiology of inhibitor development in hemophilia A. Semin Thromb Hemost 2003;29:61-8.
Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgresser M, Haack A, et al. Haemophilia A: mutation type determined risk of inhibitor formation. Thromb Haemost 1995,74:1402-6.
พันธุ์เทพ อังชัยสุขศิริ. New antiplatelet agents. ประชุมวิชาการประจำปี ครั้งที่ 22 สมาคมโลหิตวิทยาแห่งประเทศไทย"Hematology 2001" หน้า 37-66.
Nuss R, Soucie JM, Evatt B; Hemophilia Surveillance System Project Investigators. Changes in the occurrence of and risk factors for hemophilia-associated intracranial hemorhage. Am J Hematol 2001,63:37-42.
Schmidt ML, Garmerman S, Smith HE, Scott JP, DiMichele DM. Recombinant activated factor VII (IFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors. Am J Hematol 1994;47.36-40.
Hathaway WE, Christian MJ, Clarke SL, Hasiba U. Comparison of continuous and intermittent factor VIII concentrate therapy in hemophilia A. Am J Hematol 1984;17:85-8.
Martinowitz U, Varon D. Continuous infusion therapy in hemophilia. Hemophilia 1998;4:413-35.
Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003:9:272-8.
van de Berg HM, Fischer K. Prophylaxis for severe hemophilia: Experience from Europe and the United States. Semin Thromb Hematol 2003;29:49-54.
Astermark J. Treatment of the bleeding inhibitor patient. Semin Thromb Hematol 2003;29:77-85.
Ewenstein BM. Continuous infusion of recombinant factor VIIa. Thromb Haemost 2001,86:942-4.
Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIl inhibitor bypassing activity (FEIBA@): 10 years complication of thrombotic adverse events. Haemophilia 2002;8:83-90.
Key NS, Christie B, Henderson N, Nelsestuen GL. Possible synergy between recombinant factor VIla and prothrombin complex concentrate in hemophilia therapy. Thromb Haemost 2002,88:60-5.
Sheth S, Dimichele D, Lee M, Lamour J, Guaebeur J, Hsu D, et al. Heart transplant in a factor VIIldeficient patient with a high-titre inhibitor: perioperative management using high-dose continuous infusion factor VIII and recombinant factor VIIa. Haemophilia 2001:7:227-32.
Mannucci PMM.Hemostatic drugs. N Engl J Med 1998:339:245-53.
Ingerslev J, Feldstedt M, Pedersen SS. Control of haemostasis with recombinant factor VIla in patients with inhibitor to factor VII. Lancet 1991,338:831-2.
Smith OP, Hann IM. IFVIIa therapy to secure haemostasis during central line insertion in children with high-responding FVIII inhibitors. Br J Haematol 1996;92:1002-4.
Mariani G, Siraghsa S, Kroner BL. Immune tolerance induction in hemophilia A: a review. Semin Thromb Hematol 2003;29:69-75.
อำไพวรรณ จวนสัมฤทธิ์, ผกายมาศ ปิณฑะดิษ, ภัทรพร อิศรางกูร ณ อยุธยา และคณะ. การศึกษาภาวะที่มียีนโรคฮีโมพีเลีย เอ แฝง. รามาธิบดีเวชสาร 2533,13.1-7.
Pintadit P, Chuansumrit A, Chotsupakarn, et al. Carrier detection in hemophilia A by using the ratio of factor VIIl clotting activity and von Willebrand factor antigen. Thai J of Hematol Transf Med 1996;6:24-31.
Chuansumrit A, Ajimakom S, Sasanakul W, Sugkraroek P, Parinayok R, Hongtrakul P, et al. Prenatal diagnosis of hemophilia A in Thailand. Mahidol J 1998;5:87-90.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
